Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies. Badger Meter is accused of pulling forward customer orders to conceal weakening demand. PicS faces allegations of misrepresenting credit quality and undisclosed credit deterioration ahead of its IPO. Verra Mobility is charged with overstating growth prospects dependent on a single customer relationship. Grail is accused of providing misleading confidence about clinical trial results. Investors have until early August 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against GRAIL, Inc. alleging that company executives made materially false and misleading statements regarding the NHS-Galleri trial's likelihood of success. The complaint claims defendants misrepresented the trial's prospects and concealed adverse data trends, with the class period spanning May 13, 2025 to February 19, 2026. Investors have until August 4, 2026 to request lead plaintiff status.

Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 billion in market capitalization. The class action period spans May 13, 2025 to February 19, 2026, with a lead plaintiff deadline of August 4, 2026.

Law firm Robbins Geller Rudman & Dowd LLP announced class action lawsuits against GRAIL, Inc. (NASDAQ: GRAL) for allegedly making false statements about its NHS-Galleri cancer screening trial. GRAIL failed to achieve the primary endpoint of reducing Stage III-IV cancers, causing the stock to fall over 50% on February 19, 2026. The firm is seeking lead plaintiffs from investors who purchased GRAL stock between May 13, 2025 and February 19, 2026. Similar lawsuits were also filed against Commvault Systems, Inc. and PicS N.V.

Grail, Inc. (NASDAQ: GRAL) faces a class action securities fraud lawsuit after failing to meet the primary endpoint in its NHS-Galleri cancer trial on February 19, 2026. The announcement caused the stock to plummet 50.5%. Investors allege the company made materially false statements about trial results and failed to disclose that the three-year timeline was insufficient to demonstrate the primary endpoint, misleading shareholders about business prospects.

Grail's stock crashed 50% in February after its NHS-Galleri multi-cancer early detection test failed to meet its primary endpoint of reducing late-stage cancer detection. However, the stock has partially recovered on optimism about favorable results in 12 specific cancer types. The company's future depends on FDA approval and insurer adoption, which will hinge on cost-benefit analyses by medical insurers.

Rosen Law Firm has filed class action lawsuits on behalf of investors in Insulet Corporation (PODD), GRAIL, Inc. (GRAL), and GeneDx Holdings Corp. (WGS). The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety compliance, and regulatory risks. Investors who purchased securities during the specified class periods may be eligible for compensation. The lead plaintiff deadline is August 31, 2026.

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The company allegedly concealed that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The lead plaintiff deadline is August 4, 2026.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Berger Montague has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL failed to disclose that the NHS-Galleri trial was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. On February 19, 2026, GRAIL announced the trial's primary endpoint had not been met, causing the stock to plummet approximately 50.55% in a single trading day from $101.53 to $50.21 per share. The lead plaintiff deadline is August 4, 2026.

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The complaint claims defendants provided overly positive statements while concealing material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be entitled to compensation. The lead plaintiff deadline is August 4, 2026.

Bernstein Liebhard LLP has announced multiple securities class action lawsuits against Megan Holdings Limited (MGN), Photronics, Inc. (PLAB), and GRAIL, Inc. (GRAL). The lawsuits allege that defendants made materially false and misleading statements regarding their businesses and operations, causing securities to trade at artificially inflated prices. Investors who suffered losses during the respective class periods are encouraged to contact the firm.